Skip to content

Alumis Inc. ALMS Cash & Equivalents

Cash & Equivalents at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$9.57B-12.0%
Amgen logo
AmgenAMGN
$559M+10.0%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$49.52M-40.7%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$35.73M+109%
Immunome logo
ImmunomeIMNM
$582.69M+126%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$5.7M-20.0%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.12B+739%
Enterprise value$3.1B+1,238%
P/S371.9×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s cash & equivalents?
Alumis Inc. (ALMS) reported cash & equivalents of $63.89M in Q1 2026.
How has Alumis Inc.'s cash & equivalents changed year-over-year?
Alumis Inc.'s cash & equivalents decreased by 50.3% year-over-year, from $128.54M to $63.89M.
What is the long-term trend for Alumis Inc.'s cash & equivalents?
Over 2 years (2023 to 2025), Alumis Inc.'s cash & equivalents has grown at a 39.6% compound annual growth rate (CAGR), from $46M to $89.67M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.